{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T06:42:48Z","timestamp":1793083368046,"version":"4.5.0"},"reference-count":97,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2018,2,2]],"date-time":"2018-02-02T00:00:00Z","timestamp":1517529600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2018,2,2]],"date-time":"2018-02-02T00:00:00Z","timestamp":1517529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Alzheimer's Disease Reports"],"published-print":{"date-parts":[[2018,3,6]]},"abstract":"<jats:p>It is almost ten years since the Banerjee 2009 report established that inappropriate prescribing of antipsychotics in the elderly was occurring in the UK and such patients had an 85% increased risk of adverse events and greater mortality. This report was a critical analysis addressing the outcomes of treatment practices for dementia in UK patients and globally, aimed at reducing prescribing of antipsychotic drugs for dementia. Since 2009, many significant studies worldwide (including several more recent large retrospective studies) provide more extensive longitudinal data for the adverse impacts of antipsychotic drugs in dementia. We have used the data in these studies including from over 380,000 dementia patients, with 85,069 prescribed antipsychotic agents as well as from 359,235 non-dementia antipsychotic drug users to provide an up-dated meta-analysis. This is the first meta-analysis to include evidence from general mental health studies showing that antipsychotic drugs precipitate excessive mortality across the spectrum. Prescribing of antipsychotic drugs for dementia or for other mental health care should be avoided and alternative means sought for handling behavioral disorders of such patients.<\/jats:p>","DOI":"10.3233\/adr-170042","type":"journal-article","created":{"date-parts":[[2018,2,6]],"date-time":"2018-02-06T12:57:34Z","timestamp":1517921854000},"page":"1-26","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":135,"title":["Increased All-Cause Mortality by Antipsychotic Drugs: Updated Review and Meta-Analysis in Dementia and General Mental Health Care"],"prefix":"10.1177","volume":"2","author":[{"given":"Stephen J.","family":"Ralph","sequence":"first","affiliation":[{"name":"Griffith University","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony J.","family":"Espinet","sequence":"additional","affiliation":[{"name":"Griffith University","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2018,2,2]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2008.07111779"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1114058"},{"key":"e_1_3_2_4_2","volume-title":"The use of antipsychotic medication for people with dementia: Time for action","author":"Banerjee S","year":"2009","unstructured":"BanerjeeS (2009) The use of antipsychotic medication for people with dementia: Time for action. Department of Health UK Government, London."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1177\/0269881108093583"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h4326"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.08m04597yel"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e977"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2011.11030347"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052827"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.15.1934"},{"key":"e_1_3_2_12_2","unstructured":"Food and Drug Administration (FDA) Public Health Advisory: Deaths with antipsychotics in elderly patients with behavioral disturbances Department of Health and Human Services U.S. Government www.fda.gov\/drugs\/drugsafety\/postmarketdrugsafetyinformationforpatientsandproviders\/ucm053171.htm 4 Nov. 2005"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-11-200706050-00006"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.061250"},{"key":"e_1_3_2_15_2","unstructured":"Food and Drug Administration (FDA) Information for Healthcare Professionals\u2014antipsychotics Department of Health and Human Services U.S. Government www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm124830.htm 16 Jun. Accessed 09\/12-2016."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mp.4002136"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61764-X"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61765-1"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2012.12030342"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-140579"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1301492"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061240"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-160671"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.15m10303"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000146"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/gps.4452"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurpsy.2016.11.013"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000161"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-151207"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jspi.2009.09.017"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.4135\/9781412985031"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1037\/1082-989X.3.4.486"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1186"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyn065"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1348\/000711010X502733"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/247486"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/647476"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-015-0262-y"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2013.764989"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-016-0060-6"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.2174\/156720512803569037"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jagp.2013.06.007"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2015.08.014"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12614"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1017\/S1041610212000117"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2015.07.008"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2016.03.006"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1159\/000326213"},{"key":"e_1_3_2_50_2","first-page":"34","article-title":"Increase in mortality rate in patients with dementia treated with atypical antipsychotics: A cohort study in outpatients in Central Italy","volume":"49","author":"Piersanti M","year":"2014","unstructured":"PiersantiM, CapannoloM, TurchettiM, SerroniN, De BerardisD, EvangelistaP, CostantiniP, OrsiniA, RossiA, MaggioR (2014) Increase in mortality rate in patients with dementia treated with atypical antipsychotics: A cohort study in outpatients in Central Italy. Riv Psichiatr 49, 34\u201340.","journal-title":"Riv Psichiatr"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1111\/psyg.12263"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-150946"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0806994"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2010.02873.x"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2014.3018"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2015.0675"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.14111"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1017\/S104161021100175X"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.11.010"},{"key":"e_1_3_2_60_2","first-page":"7","article-title":"Haloperidol clearly is neurotoxic. Should it be banned?","volume":"12","author":"Nasrallah HA","year":"2013","unstructured":"NasrallahHA (2013) Haloperidol clearly is neurotoxic. Should it be banned? Curr Psychiatry 12, 7\u20138.","journal-title":"Curr Psychiatry"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1097\/JGP.0b013e31802d0b00"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.1017\/S1041610205002243"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2013.12081046"},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.1097\/JGP.0b013e31819b8936"},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2016.01.016"},{"key":"e_1_3_2_66_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3912"},{"key":"e_1_3_2_67_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2015.03.015"},{"key":"e_1_3_2_68_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-017-0142-9"},{"key":"e_1_3_2_69_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0105376"},{"key":"e_1_3_2_70_2","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwu210"},{"key":"e_1_3_2_71_2","doi-asserted-by":"publisher","DOI":"10.1177\/0269881115578162"},{"key":"e_1_3_2_72_2","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000451"},{"key":"e_1_3_2_73_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40801-016-0084-3"},{"key":"e_1_3_2_74_2","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20420"},{"key":"e_1_3_2_75_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.nmd.0000105996.62105.07"},{"key":"e_1_3_2_76_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-2012-120913"},{"key":"e_1_3_2_77_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0122246"},{"key":"e_1_3_2_78_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2014.10.004"},{"key":"e_1_3_2_79_2","doi-asserted-by":"publisher","DOI":"10.1002\/gps.4288"},{"key":"e_1_3_2_80_2","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2016.1439"},{"key":"e_1_3_2_81_2","doi-asserted-by":"publisher","DOI":"10.5694\/mja15.01339"},{"key":"e_1_3_2_82_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.11112"},{"key":"e_1_3_2_83_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12927"},{"key":"e_1_3_2_84_2","doi-asserted-by":"publisher","DOI":"10.1177\/0004867417721018"},{"key":"e_1_3_2_85_2","article-title":"Use of antipsychotics and benzodiazepines for dementia: Time for action? What will be required before global de-prescribing?","author":"Ralph SJ","year":"2017","unstructured":"RalphSJ, EspinetAJ (2017) Use of antipsychotics and benzodiazepines for dementia: Time for action? What will be required before global de-prescribing? Dementia (London) Jan 1:1471301217746769, doi: 10.1177\/1367549417708437","journal-title":"Dementia (London)"},{"key":"e_1_3_2_86_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2017.0746"},{"key":"e_1_3_2_87_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12975"},{"key":"e_1_3_2_88_2","first-page":"441","article-title":"Reducing off-label antipsychotic use in older community-dwelling adults with dementia: A narrative review","volume":"117","author":"Bain KT","year":"2017","unstructured":"BainKT, SchwartzEJ, Chan-TingR (2017) Reducing off-label antipsychotic use in older community-dwelling adults with dementia: A narrative review. J Am Osteopath Assoc 117, 441\u2013450.","journal-title":"J Am Osteopath Assoc"},{"key":"e_1_3_2_89_2","first-page":"CD007726","article-title":"Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia","author":"Declercq T","year":"2013","unstructured":"DeclercqT, PetrovicM, AzermaiM, Vander SticheleR, De SutterAI, van DrielML, ChristiaensT (2013) Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia. Cochrane Database Syst Rev, CD007726.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_2_90_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0149984"},{"key":"e_1_3_2_91_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(08)70295-3"},{"key":"e_1_3_2_92_2","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2010.506711"},{"key":"e_1_3_2_93_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2015.06.009"},{"key":"e_1_3_2_94_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2014.06.013"},{"key":"e_1_3_2_95_2","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.13562"},{"key":"e_1_3_2_96_2","unstructured":"World Health Organization (WHO) Elder Abuse Department of Ageing and Life-Course WHO http:\/\/www.who.int\/ageing\/projects\/elder_abuse\/en\/ Accessed 21\/06-2016."},{"key":"e_1_3_2_97_2","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.13538"},{"key":"e_1_3_2_98_2","unstructured":"Alzheimer\u2019s Australia (2016) Submission to the Australian Law Reform Commission (ALRC). Response to the ALRC issues paper: Elder Abuse https:\/\/www.fightdementia.org.au\/files\/NATIONAL\/documents\/AA-Submission-to-ALRC-Elder-Abuse-Inquiry.pdf Accessed 08\/09-2016."}],"container-title":["Journal of Alzheimer's Disease Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/ADR-170042","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.3233\/ADR-170042","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/ADR-170042","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T09:56:36Z","timestamp":1777370196000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3233\/ADR-170042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,2]]},"references-count":97,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,3,6]]}},"alternative-id":["10.3233\/ADR-170042"],"URL":"https:\/\/doi.org\/10.3233\/adr-170042","relation":{},"ISSN":["2542-4823","2542-4823"],"issn-type":[{"value":"2542-4823","type":"print"},{"value":"2542-4823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,2]]}}}